Bluefin Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Bluefin Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-4,908	Closed	-$435K	–	553
2016 Q4	$435K	Buy	4,908 +87	+2%	+$7.92K	0.03%	238
2016 Q3	$465K	Buy	4,821 +660	+16%	+$62.8K	0.02%	197
2016 Q2	$357K	Buy	+4,161	New	+$373K	0.04%	237
2016 Q1	–	Sell	-7,110	Closed	-$802K	–	597
2015 Q4	$802K	Buy	7,110 +1,992	+39%	+$216K	0.06%	258
2015 Q3	$517K	Buy	5,118 +657	+15%	+$78.8K	0.03%	247
2015 Q2	$549K	Buy	4,461 +2,661	+148%	+$319K	0.03%	286
2015 Q1	$206K	Sell	1,800 -6,900	-79%	-$761K	0.02%	379
2014 Q4	$879K	Buy	8,700 +3,222	+59%	+$313K	0.05%	275
2014 Q3	$500K	Buy	5,478 +2,700	+97%	+$237K	0.03%	398
2014 Q2	$200K	Buy	+2,778	New	+$219K	0.01%	608
2013 Q3	–	Sell	-15,954	Closed	-$900K	–	480
2013 Q2	$900K	Buy	+15,954	New	+$922K	0.08%	227

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Bluefin Capital Management's IBB Position: Q1 2017 in Review

Bluefin Capital Management sold out of iShares Biotechnology ETF (IBB) in Q1 2017, closing a stake of 4,908 shares — an estimated $435K sold.

Bluefin Capital Management first reported a position in IBB in Q2 2013 and held it in 11 quarters. The position peaked at $900K in Q2 2013. 521 funds tracked by Wall St. Rank hold IBB as of Q1 2017.

Bluefin Capital Management reported no remaining iShares Biotechnology ETF position as of Q1 2017 after selling out during the quarter.
Bluefin Capital Management sold 4,908 iShares Biotechnology ETF shares in Q1 2017, an estimated $435K.
Bluefin Capital Management first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 11 quarters.
Bluefin Capital Management's iShares Biotechnology ETF position peaked at $900K in Q2 2013.
521 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2017.

Based on Bluefin Capital Management's 13F filing for Q1 2017, filed 15 May 2017.